Financhill
Sell
32

SLS Quote, Financials, Valuation and Earnings

Last price:
$1.32
Seasonality move :
-8.06%
Day range:
$1.21 - $1.33
52-week range:
$0.66 - $1.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.48x
Volume:
2.2M
Avg. volume:
4.1M
1-year change:
65.82%
Market cap:
$102.9M
Revenue:
--
EPS (TTM):
-$0.69

Analysts' Opinion

  • Consensus Rating
    SELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $5.83, SELLAS Life Sciences Group has an estimated upside of 345.29% from its current price of $1.31.
  • Price Target Downside
    According to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.31.

Fair Value

  • According to the consensus of 2 analysts, SELLAS Life Sciences Group has 345.29% upside to fair value with a price target of $5.83 per share.

SLS vs. S&P 500

  • Over the past 5 trading days, SELLAS Life Sciences Group has underperformed the S&P 500 by -13.04% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • SELLAS Life Sciences Group does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • SELLAS Life Sciences Group has grown year-over-year revenues for 0 quarters straight. In the most recent quarter SELLAS Life Sciences Group reported revenues of --.

Earnings Growth

  • SELLAS Life Sciences Group has grown year-over-year earnings for 0 quarters straight. In the most recent quarter SELLAS Life Sciences Group reported earnings per share of -$0.10.
Enterprise value:
81.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-2.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit $900K -- -- -- --
Operating Income -$38.4M -$29.1M -$32.8M -$9.4M -$7.3M
EBITDA -$38.4M -$29.1M -$32.8M -$9.4M -$7.3M
Diluted EPS -$2.22 -$1.54 -$0.69 -$0.33 -$0.10
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $9.3M $29M $22.6M $5.2M $24M
Total Assets $18.5M $38M $26M $8.1M $26.5M
Current Liabilities $4.2M $5.3M $12.6M $11.7M $10.6M
Total Liabilities $10.6M $11.3M $13.4M $11.9M $10.6M
Total Equity $7.9M $26.6M $12.6M -$3.8M $15.9M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$23.6M -$31.7M -$33.1M -$6.9M -$7.8M
Cash From Investing -- -- -- -$3M --
Cash From Financing $23.2M $19.9M $50.1M $54K $19.7M
Free Cash Flow -$28.1M -$37.2M -$33.1M -$9.9M -$7.8M
SLS
Sector
Market Cap
$102.9M
$43.3M
Price % of 52-Week High
71.2%
47.98%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
65.82%
-36.92%
Beta (5-Year)
2.424
0.753
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $1.39
200-day SMA
Buy
Level $1.22
Bollinger Bands (100)
Buy
Level 1.01 - 1.31
Chaikin Money Flow
Sell
Level -244.2M
20-day SMA
Buy
Level $1.26
Relative Strength Index (RSI14)
Buy
Level 53.64
ADX Line
Buy
Level 36.71
Williams %R
Neutral
Level -60.2958
50-day SMA
Buy
Level $1.10
MACD (12, 26)
Buy
Level 0.08
25-day Aroon Oscillator
Buy
Level 28
On Balance Volume
Neutral
Level 236.3M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (5)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Stock Forecast FAQ

In the current month, SLS has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLS average analyst price target in the past 3 months is $5.83.

  • Where Will SELLAS Life Sciences Group Stock Be In 1 Year?

    According to analysts, the consensus estimate is that SELLAS Life Sciences Group share price will rise to $5.83 per share over the next 12 months.

  • What Do Analysts Say About SELLAS Life Sciences Group?

    Analysts are divided on their view about SELLAS Life Sciences Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SELLAS Life Sciences Group is a Sell and believe this share price will drop from its current level to $4.00.

  • What Is SELLAS Life Sciences Group's Price Target?

    The price target for SELLAS Life Sciences Group over the next 1-year time period is forecast to be $5.83 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SLS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for SELLAS Life Sciences Group is a Buy. 2 of 2 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of SLS?

    You can purchase shares of SELLAS Life Sciences Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SELLAS Life Sciences Group shares.

  • What Is The SELLAS Life Sciences Group Share Price Today?

    SELLAS Life Sciences Group was last trading at $1.32 per share. This represents the most recent stock quote for SELLAS Life Sciences Group. Yesterday, SELLAS Life Sciences Group closed at $1.31 per share.

  • How To Buy SELLAS Life Sciences Group Stock Online?

    In order to purchase SELLAS Life Sciences Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
58
UPST alert for Feb 13

Upstart Holdings [UPST] is up 31.82% over the past day.

Buy
79
CFLT alert for Feb 13

Confluent [CFLT] is up 24.92% over the past day.

Buy
52
BL alert for Feb 13

BlackLine [BL] is down 18.03% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock